免疫检查点抑制剂在"特殊"NSCLC人群中:一种可行的方法?
Giuseppe Bronte1,2, Donato Michele Cosi3, Chiara Magri3
1Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica Delle Marche, Via Tronto 10/A, 60121 Ancona, Italy.
International journal of molecular sciences
|August 26, 2023
概括
免疫检查点抑制剂 (ICI) 在晚期非小细胞肺癌 (NSCLC) 中提供生存益处. 然而,由于研究数据有限,它们在老年患者,脑转移患者或特定突变患者的疗效仍然不确定.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 医学科学 医学科学 医学科学
背景情况:
- 先进的非小细胞肺癌 (NSCLC) 治疗已经转向免疫检查点抑制剂 (ICI).
- 在各种NSCLC环境中,ICI已经证明了显著的临床益处和改善的生存率.
- 在特定NSCLC患者亚组中ICI的疗效尚未得到充分证实.
研究的目的:
- 批判性地审查免疫检查点抑制剂 (ICI) 在特定非小细胞肺癌 (NSCLC) 亚种群中的疗效.
- 为了解决围绕ICI在老年患者,脑转移患者或癌基因成的NSCLC中益处的争议.
- 突出在NSCLC患者选择中需要预测ICI反应的生物标志物.
主要方法:
- 对高级非小细胞肺癌中免疫检查点抑制剂的关键III期研究的文献综述.
- 关于在临床试验中纳入和代表特殊NSCLC亚群的数据的分析.
- 对ICI在老年患者,脑转移患者和瘤基因成的NSCLC中有效性的现有证据的批判性评估.
主要成果:
- 免疫检查点抑制剂 (ICI) 在晚期非小细胞肺癌 (NSCLC) 中表现有前途.
- 然而,关键试验往往不包括或不充分代表老年患者,那些有活跃大脑转移或瘤基因成突变的患者.
- 这种有限的代表性阻碍了ICI在这些特定NSCLC群体中的疗效的概括.
结论:
- 免疫检查点抑制剂 (ICI) 在特殊非小细胞肺癌 (NSCLC) 亚种群中的有效性仍然存在争议.
- 这些患者在临床试验中的排除或代表性不足限制了对当前发现的推断.
- 预测生物标志物的开发对于优化ICI选择和NSCLC治疗策略至关重要.
更多相关视频
相关概念视频
Tumor Immunotherapy
556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


